Half-year report · Q2

Period2024-12-01 → 2025-05-31
Filed2025-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥4.3bn2024-12-01 → 2025-05-31Cons.Net sales
Revenue¥8.9bn2023-12-01 → 2024-11-30Cons.Net sales (5-year summary)
Revenue¥4.2bn2023-12-01 → 2024-05-31Cons.Net sales
Operating income¥199m2024-12-01 → 2025-05-31Cons.Operating income
Operating income¥202m2023-12-01 → 2024-05-31Cons.Operating income
Ordinary income¥183m2024-12-01 → 2025-05-31Cons.Ordinary income
Ordinary income¥390m2023-12-01 → 2024-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥212m2023-12-01 → 2024-05-31Cons.Ordinary income
Profit before tax¥183m2024-12-01 → 2025-05-31Cons.Income before income taxes
Profit before tax¥252m2023-12-01 → 2024-05-31Cons.Income before income taxes
Net income (owners)¥135m2024-12-01 → 2025-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥336m2023-12-01 → 2024-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥193m2023-12-01 → 2024-05-31Cons.Profit loss attributable to owners of parent
Net income¥135m2024-12-01 → 2025-05-31Cons.Profit loss
Net income¥193m2023-12-01 → 2024-05-31Cons.Profit loss
Total assets¥8.8bnat 2025-05-31Cons.Assets
Total assets¥8.5bnat 2024-11-30Cons.Assets
Total assets¥8.0bnat 2024-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.8bnat 2025-05-31Cons.Liabilities
Total liabilities¥5.6bnat 2024-11-30Cons.Liabilities
Net assets / equity¥2.9bnat 2025-05-31Cons.Net assets
Net assets / equity¥2.9bnat 2024-11-30Cons.Net assets
Net assets / equity¥2.7bnat 2024-05-31Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2025-05-31Cons.Cash and deposits
Cash and deposits¥745mat 2024-11-30Cons.Cash and deposits
Cash & equivalents¥1.3bnat 2025-05-31Cons.Cash and cash equivalents
Cash & equivalents¥745mat 2024-11-30Cons.Cash and cash equivalents
Cash & equivalents¥947mat 2024-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.0bnat 2023-11-30vCons.Cash and cash equivalents
Operating cash flow¥566m2024-12-01 → 2025-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥143m2023-12-01 → 2024-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥90m2023-12-01 → 2024-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥216m2024-12-01 → 2025-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥305m2023-12-01 → 2024-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥96m2023-12-01 → 2024-05-31Cons.Net cash provided by used in investment activities
Financing cash flow¥187m2024-12-01 → 2025-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥139m2023-12-01 → 2024-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥101m2023-12-01 → 2024-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥110.522024-12-01 → 2025-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥276.222023-12-01 → 2024-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥158.382023-12-01 → 2024-05-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio33.5%at 2025-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.8%at 2024-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.2%at 2024-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2024-12-01 → 2025-05-31¥4.3bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2024-12-01 → 2025-05-31¥4.3bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2024-12-01 → 2025-05-31¥184m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2024-12-01 → 2025-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2024-12-01 → 2025-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2024-12-01 → 2025-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2024-12-01 → 2025-05-31¥4.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-12-01 → 2025-05-31¥4.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-12-01 → 2025-05-31¥199m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2023-12-01 → 2024-05-31¥187m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2023-12-01 → 2024-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-12-01 → 2024-05-31¥202m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 484
ItemContextValueUnit
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember121000
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.099
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember44000
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.036
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember28000
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.023
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember25000
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.021
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember25000
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.021
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.017
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.017
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember20000
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.017
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember17000
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.014
Number of shares heldCurrentQuarterInstant524000
Shareholding ratioCurrentQuarterInstant0.431
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember2600
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember1212900
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember12129
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember4500
Number of shares issued shares voting rightsCurrentQuarterInstant1220000
Number of voting rights issued shares voting rightsCurrentQuarterInstant12129
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member2600
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member2600
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0021
Number of shares held in own name treasury shares etcCurrentQuarterInstant2600
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant2600
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0021
Cash and depositsPrior1YearInstant744643000JPY
Cash and depositsCurrentQuarterInstant1273312000JPY
Notes and accounts receivable tradePrior1YearInstant3341469000JPY
Notes and accounts receivable tradeCurrentQuarterInstant2962696000JPY
Electronically recorded monetary claims operating caPrior1YearInstant23021000JPY
Electronically recorded monetary claims operating caCurrentQuarterInstant30812000JPY
Merchandise and finished goodsPrior1YearInstant1294816000JPY
Merchandise and finished goodsCurrentQuarterInstant1268353000JPY
Work in processPrior1YearInstant417649000JPY
Work in processCurrentQuarterInstant291804000JPY
Raw materials and suppliesPrior1YearInstant489412000JPY
Raw materials and suppliesCurrentQuarterInstant398901000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-11-30pass rounding
balance sheet identityconsolidated 2025-05-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-11-30pass
statement vs summary · net assetsconsolidated 2025-05-31pass
statement vs summary · net income attributable to parentconsolidated 2023-12-01/2024-05-31pass
statement vs summary · net income attributable to parentconsolidated 2024-12-01/2025-05-31pass
statement vs summary · operating cash flowconsolidated 2023-12-01/2024-05-31pass
statement vs summary · operating cash flowconsolidated 2024-12-01/2025-05-31pass
statement vs summary · revenueconsolidated 2023-12-01/2024-05-31pass
statement vs summary · revenueconsolidated 2024-12-01/2025-05-31pass
statement vs summary · total assetsconsolidated 2024-11-30pass
statement vs summary · total assetsconsolidated 2025-05-31pass